However, targeting PI3K‐AKT signaling has been largely limited in clinic for cancer therapies in part due to the essential roles of AKT in physiological processes.[53, 54] By contrast, the first PIK3CA inhibitor, Ipelisib recently has been approved by FDA. Here, AKT1 is linked to cancer.